Carbidopa; Levodopa Patent Expiration
Carbidopa; Levodopa is Used for treating Parkinson's disease and related conditions such as post-encephalitic parkinsonism and parkinsonism from carbon monoxide or manganese intoxication. It was first introduced by Organon Llc A Sub Of Organon And Co
Carbidopa; Levodopa Patents
Given below is the list of patents protecting Carbidopa; Levodopa, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Crexont | US11986449 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
Crexont | US12109185 | Levodopa dosing regimen | Dec 21, 2041 | Impax |
Dhivy | US11033521 | Levodopa fractionated dose composition and use | Mar 28, 2039 | Avion Pharms |
Dhivy | US11439613 | Levodopa fractionated dose composition and use | Mar 28, 2039 | Avion Pharms |
Dhivy | US11819485 | Levodopa fractionated dose composition and use | Mar 28, 2039 | Avion Pharms |
Crexont | US10098845 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Crexont | US10292935 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Crexont | US10688058 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Crexont | US10973769 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Crexont | US10987313 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Crexont | US11357733 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Crexont | US11622941 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Crexont | US11666538 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Crexont | US12064521 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | Oct 07, 2034 | Impax |
Rytary | US8377474 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
Rytary | US8454998 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
Rytary | US8557283 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
Rytary | US9089607 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
Rytary | US9089608 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
Rytary | US9463246 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
Rytary | US9533046 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
Rytary | US9901640 | Controlled release formulations of levodopa and uses thereof | Dec 26, 2028 | Impax |
Rytary | US7094427 | Combination immediate release controlled release levodopa/carbidopa dosage forms |
May 29, 2022
(Expired) | Impax |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Carbidopa; Levodopa's patents.
Latest Legal Activities on Carbidopa; Levodopa's Patents
Given below is the list recent legal activities going on the following patents of Carbidopa; Levodopa.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jul, 2024 | US9533046 |
Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2024 | US9463246(Litigated) |
Email Notification Critical | 24 May, 2023 | US8377474(Litigated) |
Change in Power of Attorney (May Include Associate POA) Critical | 24 May, 2023 | US8377474(Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2023 | US9089607(Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2023 | US9089608(Litigated) |
Payment of Maintenance Fee, 4th Year, Large Entity | 11 Aug, 2021 | US9901640 |
Payment of Maintenance Fee, 8th Year, Large Entity | 31 Mar, 2021 | US8557283(Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 25 Sep, 2020 | US8454998(Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 06 Aug, 2020 | US8377474(Litigated) |
Carbidopa; Levodopa's Family Patents
Explore Our Curated Drug Screens
Carbidopa; Levodopa Generic API Manufacturers
Several generic applications have been filed for Carbidopa; Levodopa. The first generic version for Carbidopa; Levodopa was by Dr Reddys Laboratories Sa and was approved on Aug 28, 1992. And the latest generic version is by Rubicon Research Private Ltd and was approved on Jun 4, 2024.
Given below is the list of companies who have filed for Carbidopa; Levodopa generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 2 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 100MG | tablet, extended release | Prescription | ORAL | AB | Feb 8, 2013 |
50MG; 200MG | tablet, extended release | Prescription | ORAL | AB | Feb 8, 2013 |
2. ACTAVIS ELIZABETH
Actavis Elizabeth Llc has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Actavis Elizabeth.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 250MG
(reference standard) | tablet | Prescription | ORAL | AB | Sep 3, 1993 |
25MG; 100MG | tablet | Prescription | ORAL | AB | Sep 3, 1993 |
10MG; 100MG | tablet | Prescription | ORAL | AB | Sep 3, 1993 |
Manufacturing Plant Locations New
Actavis Elizabeth's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Actavis Elizabeth as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
3. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Alembic.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 100MG | tablet, extended release | Prescription | ORAL | AB | Jun 5, 2019 |
50MG; 200MG | tablet, extended release | Prescription | ORAL | AB | Jun 5, 2019 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
Country | City | Firm Name | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
India |
|
4. ANI PHARMS
Ani Pharmaceuticals Inc has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Ani Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG; 100MG | tablet | Discontinued | ORAL | N/A | Jun 29, 1995 |
25MG; 100MG | tablet | Discontinued | ORAL | N/A | Jun 29, 1995 |
25MG; 250MG | tablet | Discontinued | ORAL | N/A | Jun 29, 1995 |
5. APOTEX
Apotex Inc has filed for 2 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Apotex.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
50MG; 200MG | tablet, extended release | Prescription | ORAL | AB | Jun 16, 2004 |
25MG; 100MG | tablet, extended release | Prescription | ORAL | AB | Jun 16, 2004 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
Country | City | Firm Name | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||
Canada |
| |||||||||||||
India |
|
6. APOTEX INC
Apotex Inc has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Apotex Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 250MG | tablet | Prescription | ORAL | AB | Jun 2, 2008 |
10MG; 100MG | tablet | Prescription | ORAL | AB | Jun 2, 2008 |
25MG; 100MG | tablet | Prescription | ORAL | AB | Jun 2, 2008 |
Manufacturing Plant Locations New
Apotex Inc's manufacturing plants are situated in 1 country - Canada. Given below are the details of these plant locations as well as the firm names of Apotex Inc as present at those locations.
Country | City | Firm Name | ||||||
---|---|---|---|---|---|---|---|---|
Canada |
|
7. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 100MG | tablet | Prescription | ORAL | AB | Nov 28, 2022 |
10MG; 100MG | tablet | Prescription | ORAL | AB | Nov 28, 2022 |
25MG; 250MG | tablet | Prescription | ORAL | AB | Nov 28, 2022 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
India |
|
8. DR REDDYS LABS SA
Dr Reddys Laboratories Sa has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Sa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG; 100MG | tablet | Prescription | ORAL | AB | Aug 28, 1992 |
25MG; 100MG | tablet | Prescription | ORAL | AB | Aug 28, 1992 |
25MG; 250MG | tablet | Prescription | ORAL | AB | Aug 28, 1992 |
9. IMPAX LABS
Impax Laboratories Inc has filed for 4 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Impax Labs.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 100MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Jun 8, 2010 |
50MG; 200MG | tablet, extended release | Prescription | ORAL | AB | May 14, 2004 |
10MG; 100MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Jun 8, 2010 |
25MG; 250MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Jun 8, 2010 |
10. KV PHARM
Kv Pharmaceutical Co has filed for 1 generic for Carbidopa; Levodopa. This 50mg;200mg version comes by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Kv Pharm.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
50MG; 200MG | tablet, extended release | Discontinued | ORAL | N/A | Jun 24, 2004 |
Manufacturing Plant Locations New
Kv Pharm's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Kv Pharm as present at those locations.
Country | City | Firm Name | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
United States |
|
11. MYLAN
Mylan Pharmaceuticals Inc has filed for 4 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Mylan.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
50MG; 200MG | tablet, extended release | Prescription | ORAL | AB | Sep 30, 1999 |
25MG; 100MG | tablet | Prescription | ORAL | AB | Sep 28, 2009 |
10MG; 100MG | tablet | Prescription | ORAL | AB | Sep 28, 2009 |
25MG; 250MG | tablet | Prescription | ORAL | AB | Sep 28, 2009 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
Country | City | Firm Name | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||
India |
| |||||||||||||||||
Canada |
| |||||||||||||||||
Ireland |
|
12. RANBAXY
Ranbaxy Laboratories Ltd has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBILEV. Given below are the details of the strengths of this generic introduced by Ranbaxy.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG; 100MG | tablet, for suspension | Discontinued | ORAL | N/A | Jun 10, 2005 |
25MG; 250MG | tablet, for suspension | Discontinued | ORAL | N/A | Jun 10, 2005 |
25MG; 100MG | tablet, for suspension | Discontinued | ORAL | N/A | Jun 10, 2005 |
Manufacturing Plant Locations New
Ranbaxy's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Ranbaxy as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
13. RISING
Rising Pharma Holding Inc has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Rising.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 250MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Sep 18, 2008 |
10MG; 100MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Sep 18, 2008 |
25MG; 100MG | tablet, orally disintegrating | Discontinued | ORAL | N/A | Sep 18, 2008 |
Manufacturing Plant Locations New
Rising's manufacturing plants are situated in 3 countries - United States, Mexico, India. Given below are the details of these plant locations as well as the firm names of Rising as present at those locations.
Country | City | Firm Name | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||||
Mexico |
| |||||||||||||||||||
India |
|
14. RUBICON
Rubicon Research Private Ltd has filed for 4 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Rubicon.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG; 100MG | tablet | Prescription | ORAL | AB | Sep 21, 2022 |
25MG; 250MG | tablet | Prescription | ORAL | AB | Sep 21, 2022 |
25MG; 100MG | tablet, extended release | Prescription | ORAL | AB | Jun 4, 2024 |
50MG; 200MG | tablet, extended release | Prescription | ORAL | AB | Jun 4, 2024 |
Manufacturing Plant Locations New
Rubicon's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Rubicon as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
United States |
| |||||
Canada |
| |||||
India |
|
15. SANDOZ
Sandoz Inc has filed for 2 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Sandoz.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG; 100MG | tablet | Discontinued | ORAL | N/A | Jun 29, 1995 |
25MG; 250MG | tablet | Discontinued | ORAL | N/A | Jun 29, 1995 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
Austria |
| |||||
United States |
| |||||
Spain |
| |||||
India |
|
16. SCIEGEN PHARMS INC
Sciegen Pharmaceuticals Inc has filed for 4 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Sciegen Pharms Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG; 100MG | tablet | Prescription | ORAL | AB | May 7, 2021 |
25MG; 250MG | tablet | Prescription | ORAL | AB | May 7, 2021 |
25MG; 100MG | tablet, extended release | Prescription | ORAL | AB | Oct 5, 2021 |
50MG; 200MG
(reference standard) | tablet, extended release | Prescription | ORAL | AB | Oct 5, 2021 |
17. SCS
Scs Pharmaceuticals has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Scs.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG; 100MG | tablet | Discontinued | ORAL | N/A | Mar 25, 1994 |
25MG; 250MG | tablet | Discontinued | ORAL | N/A | Mar 25, 1994 |
25MG; 100MG | tablet | Discontinued | ORAL | N/A | Mar 25, 1994 |
Manufacturing Plant Locations New
Scs's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Scs as present at those locations.
Country | City | Firm Name | ||||
---|---|---|---|---|---|---|
United States |
|
18. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Sun Pharm.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 100MG | tablet, orally disintegrating | Prescription | ORAL | N/A | Jul 31, 2009 |
25MG; 250MG
(reference standard) | tablet, orally disintegrating | Prescription | ORAL | N/A | Jul 31, 2009 |
10MG; 100MG | tablet, orally disintegrating | Prescription | ORAL | N/A | Jul 31, 2009 |
Manufacturing Plant Locations New
Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.
Country | City | Firm Name | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
| |||||||||||||||||||||||||||||
India |
|
19. SUN PHARM INDS
Sun Pharmaceutical Industries Ltd has filed for 4 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 100MG | tablet | Prescription | ORAL | AB | Oct 28, 2008 |
50MG; 200MG | tablet, extended release | Prescription | ORAL | AB | Aug 23, 2007 |
25MG; 250MG | tablet | Prescription | ORAL | AB | Oct 28, 2008 |
10MG; 100MG | tablet | Prescription | ORAL | AB | Oct 28, 2008 |
20. UCB INC
Ucb Inc has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name PARCOPA. Given below are the details of the strengths of this generic introduced by Ucb Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
10MG; 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, orally disintegrating | Discontinued | ORAL | N/A | Aug 27, 2004 |
25MG; 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, orally disintegrating | Discontinued | ORAL | N/A | Aug 27, 2004 |
25MG; 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, orally disintegrating | Discontinued | ORAL | N/A | Aug 27, 2004 |
21. WATSON LABS
Watson Laboratories Inc has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Watson Labs.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 250MG | tablet | Discontinued | ORAL | N/A | Sep 28, 1993 |
10MG; 100MG | tablet | Discontinued | ORAL | N/A | Sep 28, 1993 |
25MG; 100MG | tablet | Discontinued | ORAL | N/A | Sep 28, 1993 |
22. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Carbidopa; Levodopa. All of these versions come by the name CARBIDOPA AND LEVODOPA. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
25MG; 100MG | tablet | Discontinued | ORAL | N/A | Apr 4, 2023 |
25MG; 250MG | tablet | Discontinued | ORAL | N/A | Apr 4, 2023 |
10MG; 100MG | tablet | Discontinued | ORAL | N/A | Apr 4, 2023 |